PortfoliosLab logo
Summit Therapeutics Inc. (SMMT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US86627T1088

CUSIP

86627T108

IPO Date

Mar 5, 2015

Highlights

Market Cap

$16.90B

EPS (TTM)

-$0.34

Gross Profit (TTM)

-$40.00K

EBITDA (TTM)

-$172.32M

Year Range

$2.10 - $36.91

Target Price

$37.32

Short %

23.31%

Short Ratio

4.32

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Summit Therapeutics Inc. (SMMT) returned 29.39% year-to-date (YTD) and 414.25% over the past 12 months. Over the past 10 years, SMMT returned 8.48% annually, underperforming the S&P 500 benchmark at 10.79%.


SMMT

YTD

29.39%

1M

-6.21%

6M

18.71%

1Y

414.25%

5Y*

47.57%

10Y*

8.48%

^GSPC (Benchmark)

YTD

0.60%

1M

9.64%

6M

-0.54%

1Y

11.47%

5Y*

15.67%

10Y*

10.79%

*Annualized

Monthly Returns

The table below presents the monthly returns of SMMT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202520.48%-3.77%-6.77%25.04%-4.27%29.39%
202450.19%15.82%-8.81%-5.07%120.99%-10.19%38.46%20.19%68.72%-15.11%-0.70%-3.33%583.72%
2023-16.47%-49.30%-2.78%-24.57%23.48%53.99%-16.33%-22.86%15.43%3.74%4.64%28.57%-38.59%
2022-18.22%24.55%-10.58%-35.10%-16.35%-24.81%1.00%18.81%-0.83%-8.40%-26.61%431.25%57.99%
202148.09%-2.73%-13.29%8.52%22.76%-4.60%-1.74%8.73%-37.14%2.99%-1.55%-47.05%-42.77%
2020-4.38%-9.80%71.74%58.23%7.73%-26.49%21.89%-4.70%-0.29%-4.94%37.61%4.44%193.75%
201915.65%72.93%-20.43%-3.55%-13.88%-16.78%4.35%1.29%33.88%-7.82%-9.09%6.67%39.13%
201823.92%-14.71%10.16%1.01%2.46%-81.65%-6.12%2.17%-5.53%-23.42%-23.53%-11.54%-89.62%
201722.31%16.62%8.72%-17.14%1.09%2.43%22.74%-7.94%-2.49%-18.09%14.49%-5.86%29.44%
2016-21.74%-25.00%1.04%46.33%-13.83%-5.93%-13.47%-5.14%36.51%29.85%-10.88%-18.40%-25.57%
201521.59%-15.74%-0.57%1.75%22.61%-8.11%-12.52%-2.98%3.56%9.94%12.86%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 96, SMMT is among the top 4% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of SMMT is 9696
Overall Rank
The Sharpe Ratio Rank of SMMT is 9090
Sharpe Ratio Rank
The Sortino Ratio Rank of SMMT is 9999
Sortino Ratio Rank
The Omega Ratio Rank of SMMT is 9898
Omega Ratio Rank
The Calmar Ratio Rank of SMMT is 9999
Calmar Ratio Rank
The Martin Ratio Rank of SMMT is 9696
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Summit Therapeutics Inc. (SMMT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Summit Therapeutics Inc. Sharpe ratios as of May 16, 2025 (values are recalculated daily):

  • 1-Year: 1.40
  • 5-Year: 0.26
  • 10-Year: 0.06
  • All Time: 0.06

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Summit Therapeutics Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Summit Therapeutics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Summit Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Summit Therapeutics Inc. was 95.75%, occurring on Dec 1, 2022. Recovery took 443 trading sessions.

The current Summit Therapeutics Inc. drawdown is 37.08%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.75%Sep 12, 20171316Dec 1, 2022443Sep 9, 20241759
-59.8%Apr 7, 2015366Sep 15, 201613Oct 4, 2016379
-47.89%Sep 16, 2024141Apr 8, 202510Apr 23, 2025151
-43.41%Oct 6, 201659Dec 29, 2016151Aug 7, 2017210
-38.01%Apr 25, 202514May 14, 2025

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Summit Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Summit Therapeutics Inc., comparing actual results with analytics estimates. The company met analyst expectations for EPS in the past quarter.


-1.50-1.00-0.500.0020212022202320242025
-0.07
-0.07
Actual
Estimate

Valuation

The Valuation section provides an overview of how Summit Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for SMMT compared to other companies in the Biotechnology industry. SMMT currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for SMMT relative to other companies in the Biotechnology industry. Currently, SMMT has a P/S ratio of 753.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for SMMT in comparison with other companies in the Biotechnology industry. Currently, SMMT has a P/B value of 49.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items